{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["114(10)"],"submitter":["Chew NW"],"funding":["National University of Singapore Yong Loo Lin School of Medicine’s Junior Academic Faculty Scheme","National University of Singapore Yong Loo Lin School of Medicine's Junior Academic Faculty Scheme"],"pubmed_abstract":["<h4>Background/introduction</h4>There are little data on outcomes of COVID-19 patients with the presence of fever compared to the presence of symptoms.<h4>Aim</h4>We examined the associations between symptomology, presence of fever and outcomes of a COVID-19 cohort.<h4>Design and methods</h4>Between 23 January and 30 April 2020, 554 COVID-19 patients were admitted to a tertiary hospital in Singapore. They were allocated into four groups based on symptomology and fever-Group 1: asymptomatic and afebrile, Group 2: symptomatic but afebrile, Group 3: febrile but asymptomatic and Group 4: symptomatic and febrile. The primary outcomes were intensive care unit (ICU) admissions and mortality. The composite end-point included ICU admissions, mortality or any COVID-19 related end-organ involvement.<h4>Results</h4>There were differences in ferritin (P=0.003), C-reactive protein (CRP) levels (P<0.001) and lymphopenia (P=0.033) across all groups, with the most favourable biochemical profile in Group 1, and the least in Group 4. Symptomatic groups (Groups 2 and 4) had higher ICU admissions (1.9% and 6.0%, respectively, P=0.003) than asymptomatic groups (Groups 1 and 3). Composite end-point was highest in Group 4 (24.0%), followed by Group 3 (8.6%), Group 2 (4.8%) and Group 1 (2.4%) (P<0.001). The presence of fever (OR 4.096, 95% CI 1.737-9.656, P=0.001) was associated with the composite end-point after adjusting for age, pulse rate, comorbidities, lymphocyte, ferritin and CRP. Presence of symptoms was not associated with the composite end-point.<h4>Discussion/conclusion</h4>In this COVID-19 cohort, presence of fever was a predictor of adverse outcomes. This has implications on the management of febrile but asymptomatic COVID-19 patients."],"journal":["QJM : monthly journal of the Association of Physicians"],"pagination":["706-714"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7928573"],"repository":["biostudies-literature"],"pubmed_title":["Fever as a predictor of adverse outcomes in COVID-19."],"pmcid":["PMC7928573"],"pubmed_authors":["Cen S","Cross GB","Lim ZY","Tham SM","Li TYW","Tambyah PA","Santosa A","Ngiam JN","Sia CH","Chew NW","Yap ES"],"additional_accession":[]},"is_claimable":false,"name":"Fever as a predictor of adverse outcomes in COVID-19.","description":"<h4>Background/introduction</h4>There are little data on outcomes of COVID-19 patients with the presence of fever compared to the presence of symptoms.<h4>Aim</h4>We examined the associations between symptomology, presence of fever and outcomes of a COVID-19 cohort.<h4>Design and methods</h4>Between 23 January and 30 April 2020, 554 COVID-19 patients were admitted to a tertiary hospital in Singapore. They were allocated into four groups based on symptomology and fever-Group 1: asymptomatic and afebrile, Group 2: symptomatic but afebrile, Group 3: febrile but asymptomatic and Group 4: symptomatic and febrile. The primary outcomes were intensive care unit (ICU) admissions and mortality. The composite end-point included ICU admissions, mortality or any COVID-19 related end-organ involvement.<h4>Results</h4>There were differences in ferritin (P=0.003), C-reactive protein (CRP) levels (P<0.001) and lymphopenia (P=0.033) across all groups, with the most favourable biochemical profile in Group 1, and the least in Group 4. Symptomatic groups (Groups 2 and 4) had higher ICU admissions (1.9% and 6.0%, respectively, P=0.003) than asymptomatic groups (Groups 1 and 3). Composite end-point was highest in Group 4 (24.0%), followed by Group 3 (8.6%), Group 2 (4.8%) and Group 1 (2.4%) (P<0.001). The presence of fever (OR 4.096, 95% CI 1.737-9.656, P=0.001) was associated with the composite end-point after adjusting for age, pulse rate, comorbidities, lymphocyte, ferritin and CRP. Presence of symptoms was not associated with the composite end-point.<h4>Discussion/conclusion</h4>In this COVID-19 cohort, presence of fever was a predictor of adverse outcomes. This has implications on the management of febrile but asymptomatic COVID-19 patients.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2024-02-15T09:12:50.405Z","creation":"2021-03-07T08:18:12Z"},"accession":"S-EPMC7928573","cross_references":{"pubmed":["33533902"],"doi":["10.1093/qjmed/hcab023"]}}